Ask HopeStage to help me review this study
This record does not confirm open recruitment. We can help you understand it and explore other studies.
Study ID: NCT05586789. We help you review the study, but cannot decide medical eligibility.
CompletedNCT05586789
Ranquilon, 1 mg Tablets for anxiety
This study is completed in Russia. It is testing Ranquilon, 1 mg Tablets for anxiety.
Adjustment disorder, Anxiety, ...DrugFrom 18 Years to 70 Years
Understand this study
What is this study about?
This study evaluates the safety and effectiveness of Ranquilon for people with anxiety.
Who could participate?
This study is for people with anxiety. Listed age limits: 18 years to 70 years. Other eligibility criteria apply.
- Listed locations
- Engel's, Russia · Nizhny Novgorod, Russia and 3 more locationsSee all locations and recruitment
Compensation and expense reimbursement have not been verified for this summary.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: October 12, 2022
- Recruitment status
- Completed
- Enrollment listed in the registry
- 220
- Sponsor
- Valenta Pharm JSC
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- Russia
- Age range
- From 18 Years to 70 Years
- Official registry ID
- NCT05586789
- Official title
- A Double-blind, Randomized, Placebo-controlled, Multicenter Phase III Clinical Trial to Examine the Clinical Efficacy and Safety of Ranquilon, 1 mg Tablets in Patients With Anxiety in Neurasthenia and Adjustment Disorders
Recruitment & locations
CompletedEngel's, Russia · Nizhny Novgorod, Russia · Perm, Russia
3 more locations
- Saint Petersburg, Russia
- Saratov, Russia
- Russia
Registry details
Registry conditions (original wording)
Anxiety; Neurasthenia; Adjustment Disorders
A listed location does not confirm current availability.
Questions about this study
What is this study about?
This study evaluates the safety and effectiveness of Ranquilon for people with anxiety.
Who is behind this study?
The study sponsor is Valenta Pharm JSC.
Does this study involve medication?
Yes. The study involves medication, including Ranquilon and Placebo.
Who can participate?
This study is for people with anxiety. Listed age limits: 18 years to 70 years. Other eligibility criteria apply.
Is this study still recruiting?
The registry lists this study as completed.
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
Find a study that may fit meExplore related studies
Other studies that may be relevant based on condition, country, or study type.
CompletedNCT07628153
Mindfulness and Biofeedback for Anxiety Disorders
This study is completed. It focuses on anxiety and currently lists study information in Russian Federation.
CompletedNCT06470425
Optimizing Mental Health Management With AI-Guided (GenAIS TM) Dietary Supplementation
This study is completed. It focuses on anxiety and currently lists study information in Russian Federation.
RecruitingNCT06843044
Ranquilon for anxiety
The registry lists this study as recruiting. Study locations are listed in Russia. Confirm recruitment at each site. It is testing ranquilon for anxiety.